Mustafa Varoglu

Mustafa Varoglu is a seasoned expert in drug metabolism and pharmacokinetics (DMPK) with extensive experience in the pharmaceutical industry. Currently serving as Sr. Director of DMPK at Odyssey Therapeutics since August 2024, Mustafa previously held significant roles at Sage Therapeutics, where contributions included leadership of the Metabolism and Metabolite ID Team and direction of DMPK strategy supporting clinical development and discovery programs. Notable achievements include contributions to the NDA for Zurzuvae (zuranolone, SAGE-217) which received FDA approval for postpartum depression and leadership in various IND-enabling programs. Mustafa's previous experience spans positions at Alnylam Pharmaceuticals, Cubist Pharmaceuticals, and Diversa Corporation, coupled with a strong academic foundation in Natural Products Chemistry from the University of California, Santa Cruz, and a Bachelor of Science from The University of British Columbia.